The seventh batch of national mining will open bids for nearly 200 pharmaceutical companies to enter the bureau

01 The seventh batch of national mining will be opened soon

According to the previous official documents of the seventh batch of national procurement, all provinces need to complete the review of relevant drug procurement requirements before 17:00 on February 25

The time has come to the 21st, and the review of the seventh batch of drug procurement requirements will be completed this week

The Hunan Provincial Medical Insurance Bureau stipulated in the "Notice on Submitting the Purchase Data Related to the Scope of the Seventh Batch of Nationally Organized Centralized Purchase of Drugs" that the review time of the county, city and state medical insurance departments is from February 17, 2022 to 2022 At 24:00 on February 21, 2019 (that is, today).

According to the regular progress arrangement of procurement with volume, after the procurement demand is reviewed and reported, the stages of the announcement of the centralized procurement documents, the opening of the bid, the release of the proposed selection result, the confirmation of the official selection result and the landing time will be carried out.

A total of 26 injections were included in the seventh batch of national procurement, accounting for about 50% of the total number of varieties collected this time

It is worth noting that in this collection, multiple injections are different dosage forms of the previous collection

For example, omeprazole enteric-coated capsules were selected in the third batch of national procurement, and omeprazole injection was included in this centralized procurement; in the fifth batch of national procurement, metoprolol oral normal release was selected.

According to data from Minet.

With the new formulations of large varieties entering the centralized procurement again, the varieties covered by the national procurement have become more comprehensive

03 Nearly 200 pharmaceutical companies meet the conditions, and fierce competition is coming

On February 17, the Shanghai Sunshine Pharmaceutical Purchasing Network issued the "Notice on Launching the Seventh Batch of Nationally Organized Centralized Drug Purchasing Related Drug Information Reporting Work"., 30mg, 40mg, 50mg), etc.208 kinds of medicines

This centralized procurement also involves a number of over 1 billion varieties, and some of the products have been reviewed by more than 10 companies

The original research of tenofovir alafenamide oral normal-release dosage form is Gilead, and the companies that have reviewed it include Fujian Guangshengtang Pharmaceutical, Chengdu Yuandong Biopharmaceutical, Kelun, Qilu Pharmaceutical, Chengdu Better, Chia Tai Tianqing Pharmaceutical, etc.

.

According to Cyberland, the rules for the first five batches of centralized procurement tend to be stable—the whole country participates, and a maximum of 10 companies are allowed to be selected.
3 companies, 2 years; 4 companies and above, 3 years), 80% of the agreed procurement volume selected by 4 companies and above (50% from 1 company, 60% from 2 companies, and 70% from 3 companies)
.

The domestic patent of tenofovir alafenamide oral normal-release dosage form has expired in July 2021.
Once the seventh batch of centralized procurement is officially launched, the degree of competition it faces is self-evident
.

04 The renewal of the national procurement contract allows price increases, and enterprises usher in new opportunities

With the gradual advancement of the seventh batch of centralized procurement, the renewal of the previous batches of centralized procurement has also been launched one after another
.

On January 24, the Jilin Provincial Drug Procurement Center issued the "Notice on Announcement of the Announcement of the Result of the Bidding Renewal Project of the Selected Drugs in Jilin Province after the Expiry of the First and Third Batch of State-Organized Centralized Drug Purchasing Agreements".
A total of 16 products participated in the bid renewal.
, the prices of some drugs have increased significantly, for example, the clozapine tablets of Jiangsu Enhua Pharmaceutical Co., Ltd.
increased by more than 120%
.

It is not a new thing to increase the price of domestically sourced varieties after the renewal of the contract.
The Shaanxi Provincial Medical Insurance Bureau also proposed that the price of the last round of centralized procurement was low, and due to factors such as rising costs, the company could not continue to supply at the original selected price.
Allow the selected price to rise appropriately
.

For the selected pharmaceutical companies, allowing the renewal of the contract to increase the price is undoubtedly a good opportunity for it
.

As we all know, most of the varieties entering the centralized procurement have achieved a considerable decline
.
The first five batches of chemical drugs were collected from China, and the average decline was at least 50%, the largest at 59%, and the highest decline was over 90%
.

With the dynamic adjustment of centralized procurement prices, to a certain extent, it may stimulate the enthusiasm of enterprises to participate in centralized procurement, and under the premise of maintaining reasonable profit margins, the supply of enterprises will become more and more stable
.

Attachment: The seventh batch of domestically-picked varieties of over-evaluation enterprises + specifications (as of February 17, the table is manually sorted, if there are any mistakes, please comment and correct)